background

Patient Profiles

Page title image

Could the patients below be eligible for Optune Lua?

Explore patient profiles

david

Patient profile of David, a 55-year-old Optune Lua user with metastatic non-small cell lung cancer.
David

55 years old

25% PD-L1, stage IVa squamous cell NSCLC Durable response to IO + platinum-based chemo, now with slow progression during maintenance IO

“My doctor thinks IO is still working for me, although my cancer has shown signs of progression.*”

Patient History 

• Coronary artery disease, hypertension; 30 pack-years smoking history
• ECOG PS 0

History of Present Illness

  • 5-cm mass right upper lobe and a 1.5-cm nodule in the right middle lobe, with mediastinal and supraclavicular lymphadenopathy
  • Squamous cell carcinoma with no targetable driver mutations
  • 25% PD-L1 expression 

Treatment History 

  • Pembrolizumab + carboplatin-paclitaxel Q3W for 4 cycles, with continuation of pembrolizumab Q3W for 25 cycles 

Current Disease Status 

  • Demonstrated slow progression to the left lung after 75 weeks on pembrolizumab
  • Now with a 1-cm left lung nodule and pleural-based progression, but remaining mostly asymptomatic 
Diagram of David's lung and cancer spread visualized for metastatic non- small cell lung cancer (mNSCLC).
View the results from the Optune Lua + PD-1/PD-L1 inhibitor subgroup 

laura

Patient profile of Laura, a 73-year- old Optune Lua user with metastatic non-small cell lung cancer.
Laura

73 years old

PD-L1 negative, stage IVb squamous cell NSCLC
Motivated patient with rapidly progressing multiple new lesions

“I’m willing to try whatever treatment option my doctor recommends.*”

Patient History 

  • Married, adult children, retired
  • Person with smoking history
  • Coronary artery disease, hypertension, type 2 diabetes
  • ECOG PS 1

History of Present Illness

  • Stage IVb NSCLC: multiple small, bilateral lung nodules and a liver lesion
  • Squamous cell carcinoma with no targetable driver mutations
  • PD-L1 negative

Treatment History 

  • Nivolumab + ipilimumab + carboplatin-paclitaxel for 2 cycles, followed by nivolumab + ipilimumab for 6 cycles 

Current Disease Status 

  • Five months after initiating treatment, the patient experienced progressive disease with new bone lesions in the lower spine and a few small liver lesions 
Diagram of Laura's lung and liver cancer spread visualized for metastatic non-small cell lung cancer.
View the results from the Optune Lua + docetaxel subgroup 

susan

Patient profile of Susan, a 60-year- old Optune Lua user with metastatic non-small cell lung cancer.
Susan

60 years old

75% PD-L1, stage IVa nonsquamous NSCLC

Avoided 1L IO due to autoimmune comorbidity    

“I am exploring treatment options that will extend my survival.*”

Patient History 

  • Widowed with a caregiver, adult children. First grandchild due in 6 months
  • Never smoker
  • On active treatment for her autoimmune comorbidity
  • ECOG PS 1 

History of Present Illness

  • Stage IVa NSCLC: referred from rheumatologist. Single lung mass of 6 cm in diameter, with a 1.3-cm liver lesion
  • Nonsquamous cell carcinoma with no targetable driver mutations
  • 75% PD-L1 expression 

Treatment History 

  • Carboplatin/pemetrexed for 4 cycles with continued pemetrexed. IO was avoided given the history of her autoimmune comorbidity

Current Disease Status 

  • Radiologic assessment showed stable disease for 3 months, but she now has progressive disease in the lung and liver
Diagram of Susan's lung and liver cancer spread visualized for metastatic non-small cell lung cancer.
View the results from the Optune Lua + PD-1/PD-L1 inhibitor subgroup 
Patient receiving assistance with Optune Lua device while preparing for mNSCLC treatment.

Actor portrayals.

Review guidelines for managing skin-related adverse reactions

Learn more

1L, first line; ECOG PS, Eastern Cooperative Oncology Group performance status; IO, immuno-oncology; NSCLC, non–small cell lung cancer; PD-L1, programmed cell death 1 protein; PD-1/PD-L1, programmed cell death 1 protein/programmed cell death 1 ligand 1; Q3W, every 3 weeks.
 

 

Important Safety Information 

Contraindications 

Do not use Optune Lua® in patients with an electrical implant. Use of Optune Lua together with electrical implants has not been tested and may lead to malfunctioning of the implanted device. 

 

Do not use Optune Lua in patients known to be sensitive to conductive hydrogels. In this case, skin contact with the gel used with Optune Lua may commonly cause increased redness and itching, and rarely may even lead to severe allergic reactions, such as a fall in blood pressure and breathing difficulty.

Warnings and Precautions 

Optune Lua can only be prescribed by a healthcare provider that has completed the required certification training provided by Novocure® (the device manufacturer). 

 

Do not prescribe Optune Lua for patients who are pregnant, whom you think might be pregnant, or who are trying to get pregnant, as the safety and effectiveness of Optune Lua in these populations have not been established. 

 

The most common (≥10%) adverse events involving Optune Lua concurrent with PD-1/PD-L1 inhibitors or docetaxel were dermatitis, musculoskeletal pain, fatigue, anemia, dyspnea, nausea, cough, diarrhea, anorexia, pruritus, leukopenia, pneumonia, respiratory tract infection, localized edema, rash, pain, constipation, skin ulcers, and hypokalemia. 

 

Other potential adverse effects associated with the use of Optune Lua include treatment related skin toxicity, allergic reaction to the adhesive or to the gel, overheating of the array leading to pain and/or local skin burns, infections at the site where the arrays make contact with the skin, local warmth and tingling sensation beneath the arrays, medical device site reaction, muscle twitching, and skin breakdown or skin ulcer. 

 

If the patient has an underlying serious skin condition on the chest, evaluate whether this may prevent or temporarily interfere with Optune Lua treatment.

 

Indication For Use

Optune Lua is intended as a treatment concurrent with PD-1/PD-L1 inhibitors or docetaxel for adult patients with metastatic non-small cell lung cancer who have progressed on or after a platinum-based regimen. 

 


Please see full Instructions For Use (IFU) and Patient Information and Operation Manual (PIOM) for Optune Lua®.

Important Safety Information 

Contraindications 

Do not use Optune Lua® in patients with an electrical implant. Use of Optune Lua together with electrical implants has not been tested and may lead to malfunctioning of the implanted device. 

 

Do not use Optune Lua in patients known to be sensitive to conductive hydrogels. In this case, skin contact with the gel used with Optune Lua may commonly cause increased redness and itching, and rarely may even lead to severe allergic reactions, such as a fall in blood pressure and breathing difficulty.

Warnings and Precautions 

Optune Lua can only be prescribed by a healthcare provider that has completed the required certification training provided by Novocure® (the device manufacturer). 

 

Do not prescribe Optune Lua for patients who are pregnant, whom you think might be pregnant, or who are trying to get pregnant, as the safety and effectiveness of Optune Lua in these populations have not been established. 

 

The most common (≥10%) adverse events involving Optune Lua concurrent with PD-1/PD-L1 inhibitors or docetaxel were dermatitis, musculoskeletal pain, fatigue, anemia, dyspnea, nausea, cough, diarrhea, anorexia, pruritus, leukopenia, pneumonia, respiratory tract infection, localized edema, rash, pain, constipation, skin ulcers, and hypokalemia. 

 

Other potential adverse effects associated with the use of Optune Lua include treatment related skin toxicity, allergic reaction to the adhesive or to the gel, overheating of the array leading to pain and/or local skin burns, infections at the site where the arrays make contact with the skin, local warmth and tingling sensation beneath the arrays, medical device site reaction, muscle twitching, and skin breakdown or skin ulcer. 

 

If the patient has an underlying serious skin condition on the chest, evaluate whether this may prevent or temporarily interfere with Optune Lua treatment.

 

Indication For Use

Optune Lua is intended as a treatment concurrent with PD-1/PD-L1 inhibitors or docetaxel for adult patients with metastatic non-small cell lung cancer who have progressed on or after a platinum-based regimen. 

 


Please see full Instructions For Use (IFU) and Patient Information and Operation Manual (PIOM) for Optune Lua®.

Novocure Websites

This website is intended for US healthcare professionals seeking information on Optune Lua.

 

 

 

 

External links

OptuneGioHCP.com
OptuneLuaHCP.com/MPM
Novocuretrials.com

Quick links

About Optune Lua
Clinical Data
Patient Profiles
Dermatologic AEs
Support & Resources

Legal Links

Terms of Use
Privacy Notice
Contact Us
Novocure logo

©2025 Novocure GmbH. All Rights Reserved. 

Optune Lua, MyNovocure, MyLink, and Novocure are trademarks of Novocure GmbH.

US-OPL-00070 v3.0 July 2025